Drugs used in supraventricular tachycardia

Drugs used in supraventricular tachycardia Supraventricular tachycardia (SVT) is a rapid heart rhythm originating above the ventricles, often causing palpitations, dizziness, and shortness of breath. Managing SVT effectively requires a clear understanding of the drugs used to control or terminate episodes. Several classes of medications are employed, depending on the severity, frequency of episodes, and patient-specific factors. These medications aim to restore normal heart rhythm, prevent recurrences, and alleviate symptoms.

Drugs used in supraventricular tachycardia One of the primary acute treatments for SVT is the use of vagal maneuvers. Techniques such as the Valsalva maneuver or carotid sinus massage can sometimes terminate episodes by stimulating the vagus nerve, which slows conduction through the atrioventricular (AV) node. When vagal maneuvers are ineffective, pharmacologic intervention becomes necessary.

Adenosine is often considered the first-line drug for acute termination of SVT. It acts very rapidly by transiently blocking conduction through the AV node, which interrupts the reentrant circuit responsible for many SVT episodes. Adenosine’s onset is almost immediate, with effects lasting only a few seconds, making it highly effective and safe when administered intravenously in a monitored setting. However, patients may experience transient side effects such as flushing, chest discomfort, or shortness of breath.

For longer-term management and prevention of recurrent SVT, other classes of drugs are utilized. Calcium channel blockers, particularly verapamil and diltiazem, are frequently prescribed because they slow conduction through the AV node, thereby preventing reentrant circuits. These medications are effective both acutely and as maintenance therapy but require cautious use in patients with heart failure or hypotension. Drugs used in supraventricular tachycardia

Drugs used in supraventricular tachycardia Beta-blockers, such as metoprolol or atenolol, are another cornerstone in SVT management. They decrease sympathetic stimulation and reduce the heart’s excitability, helping to prevent episodes. Beta-blockers are especially useful in patients with coexisting conditions like hypertension or ischemic heart disease.

In some cases, antiarrhythmic drugs like propafenone or flecainide may be prescribed for rhythm control, especially in recurrent, symptomatic SVT that does not respond well to other medications. These agents work by modifying the electrical activity of the heart, decreasing the likelihood of reentrant circuits. Drugs used in supraventricular tachycardia

Drugs used in supraventricular tachycardia It’s worth noting that while these medications are effective, they should be used under medical supervision because of potential side effects and interactions. Long-term management may also involve catheter ablation, a procedure that eliminates the abnormal electrical pathway responsible for SVT, offering a potential cure for suitable candidates.

In summary, the pharmacologic treatment of SVT involves several drug classes, each with specific indications and mechanisms of action. Adenosine is the drug of choice for acute episodes, while calcium channel blockers, beta-blockers, and antiarrhythmic agents serve as mainstays for prevention and long-term control. Tailoring therapy to individual patient profiles ensures optimal outcomes and quality of life.